登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Oral Paclitaxel Solution With Immunotherapy and Concurrent SBRT as Neoadjuvant Treatment for Older Adults With NSCLC
ClinicalTrials.gov 上登记的一项肺癌开放试验,由上海市肺科医院牵头,本站收录的另外 2 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 3
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
- 牵头方上海市肺科医院Shanghai Pulmonary Hospital上海医院页面
- 研究中心广东省人民医院Guangdong Provincial People's Hospital广州医院页面
- 研究中心浙江省肿瘤医院Zhejiang Cancer Hospital杭州医院页面
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07754812,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 5
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(5 项)收起清单
70 岁 至 未注明;性别:不限
登记记录的入选字段
Histologically confirmed non-small cell lung cancer, clinical stage IIA-IIIB according to the 8th edition of the AJCC staging system.
入选标准第 3 条
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
入选标准第 2 条
No sensitizing driver alterations in EGFR, ALK, ROS1, or other tested actionable genes.
入选标准第 6 条
Absolute neutrophil count at least 1.5 × 10\^9/L, platelet count at least 100 × 10\^9/L, and hemoglobin at least 9 g/dL.
入选标准第 8 条
Total bilirubin no more than 1.5 × the upper limit of normal; alanine aminotransferase and aspartate aminotransferase no more than 2.5 × the upper limit of normal.
入选标准第 9 条
Serum creatinine no more than 1.5 × the upper limit of normal or creatinine clearance at least 60 mL/min.
入选标准第 10 条
Another concurrent malignancy or a history of another malignancy cured less than 5 years before enrollment, except adequately treated cervical carcinoma in situ or basal cell or squamous cell carcinoma of the skin.
排除标准第 2 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);既往治疗;影像与可测量病灶;怀孕、哺乳与避孕。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07754812,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Age 70 years or older, regardless of sex. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Histologically confirmed non-small cell lung cancer, clinical stage IIA-IIIB according to the 8th edition of the AJCC staging system. No evidence of distant metastasis and considered suitable for radical lung cancer surgery. The primary lung lesion is suitable for stereotactic body radiotherapy. No sensitizing driver alterations in EGFR, ALK, ROS1, or other tested actionable genes. Adequate major organ function, including all of the following: Absolute neutrophil count at least 1.5 × 10\^9/L, platelet count at least 100 × 10\^9/L, and hemoglobin at least 9 g/dL. Total bilirubin no more than 1.5 × the upper limit of normal; alanine aminotransferase and aspartate aminotransferase no more than 2.5 × the upper limit of normal. Serum creatinine no more than 1.5 × the upper limit of normal or creatinine clearance at least 60 mL/min. Urine protein less than 1+; if urine protein is 1+, 24-hour urine protein must be less than 500 mg. Blood glucose within the normal range or stable glycemic control in participants with diabetes. Baseline forced expiratory volume in 1 second (FEV1) at least 2 L; if FEV1 is less than 2 L, the predicted postoperative FEV1 must be greater than 800 mL as assessed by a thoracic surgeon. No myocardial infarction within the previous year, no unstable angina, no symptomatic severe arrhythmia, and no cardiac insufficiency. The participant has been fully informed and voluntarily provides written informed consent.排除标准:Exclusion Criteria:
Prior lobectomy, thoracic radiotherapy, or systemic antitumor therapy. Another concurrent malignancy or a history of another malignancy cured less than 5 years before enrollment, except adequately treated cervical carcinoma in situ or basal cell or squamous cell carcinoma of the skin. Active autoimmune disease or a history of autoimmune disease requiring systemic immunosuppressive treatment. Active infection requiring systemic treatment, active tuberculosis, human immunodeficiency virus infection, active hepatitis B or hepatitis C, active syphilis, or another active transmissible infection specified by the protocol. Severe cardiac, hepatic, renal, or metabolic disease that precludes surgery or study treatment. History of interstitial lung disease or drug-induced pneumonitis, or imaging evidence of active interstitial lung disease. Uncontrolled large pleural effusion or pericardial effusion. Major surgery, severe trauma, or treatment with another investigational drug within 4 weeks before enrollment. Recent receipt of an anticancer vaccine or live vaccine. Any other condition that, in the investigator's opinion, makes the participant unsuitable for the study or may interfere with interpretation of the study results.
引自 ClinicalTrials.gov, NCT07754812, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07754812,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。